The Need

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia worldwide. While there are some indications of genetic predisposition, the etiology of the disease is primarily unknown, but it does progress with age. Diagnosis of the disease is critical at an early time point and is a high priority for healthcare, due to the aging population. AD is characterized by the presence of neurofibillary tangles, which are microtubule aggregates associated with the protein tau. Immunoassays have been developed recently that detect tau in biological specimens, providing a means for premortem diagnosis of Alzheimer’s disease. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains.

The Technology

Ohio State University researchers, led by Dr. Jeffrey Kuret, have developed detection methods for tau protein methylation in human samples. The approach is capable of capturing both site distribution and stoichiometry of this post-translational modification. The resulting tau methylation signature changes with disease progression and may have utility for detection of Alzheimer's disease-related changes in bodily fluids. In addition to this application, the approach provides a method of generating antibodies and tau peptides that can be used for treatment of Alzheimer's disease in patients.

Commercial Applications

• Alzheimer's disease diagnosis and identification

Benefits/Advantages

• Early detection of Alzheimer's disease through monitoring tau protein methylation non-invasively through bodily fluids
• Sensitive and specific detection of disease presence through antibody-based methods
• Changes in tau can be identified early in disease allowing for earlier treatment and care
• Provides diagnosis earlier in the onset of disease